Siluria’s investors include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital and Presidio Ventures.
Siluria's board members are:
Dr. Leighton Read, Alloy Ventures
Dr. Leighton Read is a General Partner in four Alloy funds. Before joining Alloy, Leighton spent 14 years as a biotechnology entrepreneur and investor. He co-founded Affymax NV, setting the stage for two successful spin-outs: Affymetrix and Maxygen. He founded Aviron, where he served as Chairman and CEO until 1999 and Director until its acquisition by MedImmune in 2002. While at Alloy, he served as the first CEO of Avidia, a spin-out of Maxygen later acquired by Amgen. He received a B.S. from Rice University in Psychology and Biology (1973), an MD from the University of Texas Health Science Center at San Antonio (1976), and completed internal medicine training at Duke and the Peter Bent Brigham Hospital in Boston where he held appointments at the Harvard Medical School and School of Public Health. Dr. Leighton is a director of Alexza Pharmaceuticals, AnaptysBio, Apptera, Cambrios Technologies, Genomatica, Opal Therapeutics, and Siluria. He also serves as a trustee or director of The BeneTech Initiative, BioVentures for Global Health, The UC Berkeley Foundation and School of Public Health Council and the Santa Fe Institute. His awards include several as co-inventor of technology underlying the Affymetrix GeneChip.
Clinton Bybee, ARCH Venture Partners
“Siluria is driving an enormous, global opportunity to create valuable commodity fuel and chemicals from a growing natural resource, creating thousands of jobs in the process.”
Clinton Bybee is a co-founder and Managing Director of ARCH Venture Partners. Mr. Bybee concentrates primarily on advanced materials, electronics, semiconductors, photonics, and infrastructure businesses. Mr. Bybee has helped organize and finance numerous companies including MicroOptical Devices (acquired by EMCORE), Cambrios Technologies, Aveso, Innovalight, Intelligent Reasoning Systems (acquired by Photon Dynamics), Semprius, Nanosys, and Xtera Communications. He is a board member of Impinj, Innovalight, Cambrios Technologies, Xtera Communications, Nitronex and Aveso. Mr. Bybee is an organizing member of the Texas Venture Capital Association and currently serves as its first President. Previously, Mr. Bybee worked with ARCH Development Corporation. He also managed a venture investment fund for the State of Illinois and was a production engineer with Amoco Corporation. Mr. Bybee holds an M.B.A. from the University of Chicago and a B.S. in Engineering from Texas A&M University.
Dr. Bill Joy, Kleiner Perkins Caufield & Byers
"Siluria's technology turns natural gas into fuels and materials with the right economics. The resulting products have the potential for lower-carbon emissions and can bring new sources of fuel and chemicals in regions, such as the United States, which have large supplies of natural gas but far less raw materials than they consume. Using methane and Siluria's technology to replace imported crude will not only be very profitable but help address energy-security and climate change."
Dr. Bill Joy joined KPCB in 2005 as a partner in KPCB’s Greentech Practice. He helped develop KPCB’s strategy of funding game-changing technologies broadly addressing the twin problems of climate change and sustainability. He is working broadly on ventures in areas such as wind, solar and thermoelectric power generation; low-cost electrical energy storage; renewable fuels and green chemicals from non-fuel sources; low-embodied-energy materials; energy-efficient electronics; and other areas. Dr. Joy was previously a founder and Chief Scientist of Sun Microsystems, where he was a key designer involved with a number of Sun technologies. As an inventor, He is named on more than 40 patents. Dr. Joy’s many contributions were recognized in a Fortune cover story which called him the “Edison of the Internet.” He has a Bachelor’s degree in Electrical Engineering from the University of Michigan, a Master’s degree in Computer Science from the University of California, Berkeley, and a Ph.D. in Engineering, honoris causa, from the University of Michigan. Dr. Joy is a member of the National Academy of Engineering and the American Academy of Arts and Sciences, and is a trustee of the Aspen Institute.
The Wellcome Trust
The Wellcome Trust is a UK-based global foundation with a $23 billion investment portfolio and a AAA/Aaa credit rating. The Wellcome Trust joins Siluria’s founding investors Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers (KPCB), Altitude Life Science Ventures, Lux Capital, and Presidio Ventures, all of whom returned to participate in Series B.
Dr. Angela Belcher, MIT
Dr. Belcher is the Germehausen Professor of Materials Science and Engineering, and Professor of Biological Engineering at MIT where she developed her nano-wire technology upon which Siluria’stechnology is based. Angela Belcher is world reknowned materials chemist with expertise in biomaterials, biomolecular materials, organic-inorganic interfaces and solid-state chemistry. She received her B.S. in Creative Studies and her PhD in Inorganic Chemistry from The University of California Santa Barbara. Dr. Belcher joined the faculty at MIT as the John Chipman Professor of Materials Science and Engineering and Biological Engineering in 2002. In 2006 she wasappointed Germeshausen Professor of Materials Science and Engineering and Biological Engineering. She was awarded the 24th annual MacArthur Foundation Fellowship, and the 2004 Four Star General Recognition Award. Her research has been published in various scientific journals.
Mark Noetzel
Mark Noetzel joined the Siluria Board of Directors in October, 2011. He combines experience with both large, publicly-traded firms and high technology start-ups. Currently, he is Chairman of the Board of Directors of Georgia Gulf Corporation (NYSE – GGC). Mark is also a Chairman of Aspen Aerogels, Inc., a private firm. From 2007 to 2009, he was Chief Executive Officer and President of Cilion, Inc., a venture-backed biofuels company. Prior to joining Cilion, Mr. Noetzel was with BP and Amoco for 26 years, leading multi-billion dollar businesses in the fuels and chemical industry in the US, Europe and Asia. In 2003, he was appointed Group Vice President with responsibility for BP’s $65 billion revenue retail operations and fuels transport and wholesaling in the US, Europe and Asia. Mr. Noetzel directed major parts of BP’s portfolio for a decade, having been named a Group Vice President in 1996. Previously, he was Group Vice President with responsibility for BP’s Fuels Operations in China, Africa and Australasia, and the aviation businesses, and prior to that in BP and Amoco’s chemical businesses across a broad range of chemical manufacturing and marketing activities. Mr. Noetzel was instrumental in the growth of BP’s chemical business in East Asia where he lived for almost six years. Mark Noetzel holds a BA in international relations/political science from Yale University in 1979 and an MBA from the Wharton School of the University of Pennsylvania.
Dr. Alex Tkachenko, President of Siluria Technologies
Dr. Tkachenko joined Siluria in 2008 and is business co-founder of the company. He brings a unique combination of commercial and technical expertise to Siluria drawing upon deep, global experience in the the biotech and chemical engineering sectors. Prior to Siluria, Dr. Tkachenko was Vice President, Corporate Development and Strategic Planning of Hana Biosciences, Inc (NASDAQ: HNAB), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. Prior to joining Hana, Dr. Tkachenko was employed by Genentech, Inc., most recently as an Associate Director in its development organization, where he led the Companion Diagnostics initiative to maximize clinical benefit from Genentech’s therapeutics by improving patient selection and trial design. Dr. Tkachenko earned a Ph.D. in Molecular Biology from the University of Medicine and Dentistry of New Jersey and an MBA from Harvard Business School. Earlier, Dr. Tkachenko served as a squad leader in the Soviet Army and completed a tour of combat duty in Afghanistan.
|
